Human cytomegalovirus vaccine

1. A method of treating an immunocompromised organ transplant recipient subject having a cytomegalovirus (CMV) infection, comprising administering to the subject a therapeutically effective amount of:

(i) an HCMV vaccine comprising an RNA polynucleotide having an open reading frame encoding HCMV antigenic polypeptide pp65, and

(ii) an HCMV vaccine comprising at least one RNA polynucleotide having one or more open reading frames encoding HCMV antigenic polypeptides gH, gL, UL128, UL130, and/or UL131A; and an RNA polynucleotide having an open reading frame encoding HCMV antigenic polypeptide gB;

wherein the HCMV vaccine of (i) and the HCMV vaccine of (ii) are formulated within cationic lipid nanoparticles, and wherein the lipid nanoparticles comprise a molar ratio of 20-60% ionizable cationic lipid, 5-25% non-cationic lipid, 25-55% sterol, and 0.5-15% PEG-modified lipid.

2. The method of claim 1 , wherein the pp65 polypeptide contains a deletion of amino acids 435-438.

3. The method of claim 1 , wherein the HCMV vaccine of (ii) comprises: an RNA polynucleotide having an open reading frame encoding HCMV antigenic polypeptide gH; an RNA polynucleotide having an open reading frame encoding HCMV antigenic polypeptide gL; an RNA polynucleotide having an open reading frame encoding HCMV antigenic polypeptide UL128; an RNA polynucleotide having an open reading frame encoding HCMV antigenic polypeptide UL130; an RNA polynucleotide having an open reading frame encoding HCMV antigenic polypeptide UL131A; and an RNA polynucleotide having an open reading frame encoding HCMV antigenic polypeptide gB.

4. The method of claim 1 , wherein the one or more of the RNA polynucleotides in the HCMV vaccine of (i) and/or the HCMV vaccine of (ii) are messenger ribonucleotide polynucleotides (mRNA), and wherein each mRNA polynucleotide contains a 5′ terminal CAP structure, a 5′ untranslated region (UTR), an open reading frame (ORF), a 3′ untranslated region (UTR) and a 3′ terminal poly-A tail.

5. The method of claim 1 , wherein one or more of the RNA polynucleotides in the HCMV vaccine of (i) and/or the HCMV vaccine of (ii) are codon optimized.

6. The method of claim 1 , wherein at least one of the RNA polynucleotides encodes an antigenic polypeptide having at least 90% identity to any of the amino acid sequences of SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 77, and SEQ ID NOs: 80-83.

7. The method of claim 1 , wherein the HCMV vaccine of (i) and/or the HCMV vaccine of (ii) further comprises a pharmaceutically acceptable carrier or excipient.

8. The method of claim 1 , wherein the transplant recipient is a hematopoietic cell transplant recipient.

9. The method of claim 1 , wherein the transplant recipient is a solid organ transplant recipient.

10. The method of claim 1 , wherein at least one RNA polynucleotide further comprises a 5′ terminal cap, 7mG(5′)ppp(5′)NlmpNp.

11. The method of claim 1 , wherein at least 80% of the uracil in the open reading frame of (i)-(ii) have a chemical modification selected from 1-methyl-pseudouridine or 1-ethyl-pseudouridine.

12. The method of claim 10 , wherein the chemical modification is in the carbon-5 position of the uracil.

13. The method of claim 1 , wherein the ionizable cationic lipid comprises the following compound:

14. The method of claim 1 , wherein the RNA polynucleotides are not self-replicating RNA.

15. The method of claim 1 , wherein the HCMV vaccine of (i) is administered at a dose of between 10 μg and 400 μg.

16. The method of claim 1 , wherein the HCMV vaccine of (ii) is administered at a dose of between 10 μg and 400 μg.

17. The method of claim 1 , wherein the vaccine of i) and the vaccine of ii) are administered to the individual via a route selected from the group consisting of intramuscular administration, intradermal administration and subcutaneous administration.